These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16481597)

  • 1. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
    NINDS NET-PD Investigators
    Neurology; 2006 Mar; 66(5):664-71. PubMed ID: 16481597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.
    NINDS NET-PD Investigators
    Clin Neuropharmacol; 2008; 31(3):141-50. PubMed ID: 18520981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
    JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
    Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
    Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease.
    NINDS NET-PD Investigators
    Neurology; 2007 Jan; 68(1):20-8. PubMed ID: 17200487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
    Elm JJ;
    Mov Disord; 2012 Oct; 27(12):1513-21. PubMed ID: 23079770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
    Gordon PH; Cheung YK; Levin B; Andrews H; Doorish C; Macarthur RB; Montes J; Bednarz K; Florence J; Rowin J; Boylan K; Mozaffar T; Tandan R; Mitsumoto H; Kelvin EA; Chapin J; Bedlack R; Rivner M; McCluskey LF; Pestronk A; Graves M; Sorenson EJ; Barohn RJ; Belsh JM; Lou JS; Levine T; Saperstein D; Miller RG; Scelsa SN;
    Amyotroph Lateral Scler; 2008 Aug; 9(4):212-22. PubMed ID: 18608093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
    ; Kieburtz K; Tilley BC; Elm JJ; Babcock D; Hauser R; Ross GW; Augustine AH; Augustine EU; Aminoff MJ; Bodis-Wollner IG; Boyd J; Cambi F; Chou K; Christine CW; Cines M; Dahodwala N; Derwent L; Dewey RB; Hawthorne K; Houghton DJ; Kamp C; Leehey M; Lew MF; Liang GS; Luo ST; Mari Z; Morgan JC; Parashos S; Pérez A; Petrovitch H; Rajan S; Reichwein S; Roth JT; Schneider JS; Shannon KM; Simon DK; Simuni T; Singer C; Sudarsky L; Tanner CM; Umeh CC; Williams K; Wills AM
    JAMA; 2015 Feb; 313(6):584-93. PubMed ID: 25668262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
    Parashos SA; Swearingen CJ; Biglan KM; Bodis-Wollner I; Liang GS; Ross GW; Tilley BC; Shulman LM;
    Arch Neurol; 2009 Sep; 66(9):1099-104. PubMed ID: 19597081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
    Stevens KN; Creanor S; Jeffery A; Whone A; Zajicek J; Foggo A; Jones B; Chapman R; Cocking L; Wilks J; Webb D; Carroll C;
    JAMA Neurol; 2022 Dec; 79(12):1232-1241. PubMed ID: 36315128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A futility study of minocycline in Huntington's disease.
    Huntington Study Group DOMINO Investigators
    Mov Disord; 2010 Oct; 25(13):2219-24. PubMed ID: 20721920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
    Shoulson I
    Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
    Wills AM; Li R; Pérez A; Ren X; Boyd J;
    J Neurol; 2017 Aug; 264(8):1746-1753. PubMed ID: 28712000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
    Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
    Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Freezing of gait in PD: prospective assessment in the DATATOP cohort.
    Giladi N; McDermott MP; Fahn S; Przedborski S; Jankovic J; Stern M; Tanner C;
    Neurology; 2001 Jun; 56(12):1712-21. PubMed ID: 11425939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.